Article
Oncology
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Summary: EGFR-mutated NSCLC patients with L858R mutation are more likely to respond well to ICI treatment. The occurrence of T790M resistance mutation before ICI treatment did not differ significantly between different response groups. Patients with shorter duration of EGFR-TKI pretreatment are more likely to respond well to ICI treatment.
Article
Oncology
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Summary: This study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs), but is sensitive to 3rd generation EGFR TKIs. In addition, the study identifies that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.
CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Rui-Lian Chen, Ling-Ling Sun, Yang Cao, Han-Rui Chen, Jing-Xu Zhou, Chu-Ying Gu, Ying Zhang, Si-Yu Wang, Wei Hou, Li-Zhu Lin
Summary: This meta-analysis demonstrates that adjuvant EGFR-TKI therapy could significantly prolong DFS in patients with resected EGFR-mutant NSCLC. Treatment with osimertinib showed improved DFS with a lower risk of brain recurrence than treatment with gefitinib or erlotinib for resected disease.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yahua Wu, Bin Du, Chengliu Lv, Xiaohui Ji, Jinhuo Lai
Summary: A novel LAPS score was established to facilitate individualized treatment for patients with advanced EGFR-mutant NSCLC receiving EGFR-TKI with or without bevacizumab. The analysis showed that the combination of EGFR-TKI and bevacizumab resulted in significantly longer PFS compared to EGFR-TKI monotherapy. The LAPS score can stratify patients into different risk groups, and high-risk patients benefit from the combination therapy in terms of PFS and DCR.
ANNALS OF MEDICINE
(2023)
Article
Oncology
Jin-Fei Si, Jing Xiang, Jing-Wen Wei, Yue Hao, Zheng-Bo Song
Summary: This study aims to explore the efficacy of first-generation EGFR-TKI in treating lung SCC patients and identify potential beneficial subgroups of EGFR-mutated lung SCC patients. The results showed that lung SCC patients with EGFR mutation who received first-generation EGFR-TKI had a longer PFS but similar OS compared to patients with EGFR wild type. The efficacy of first-generation EGFR-TKI in EGFR-mutated SCC patients was similar regardless of whether it was used as a first-line or second-line treatment.
Article
Biochemistry & Molecular Biology
Nguyen Quoc Khanh Le, Quang Hien Kha, Van Hiep Nguyen, Yung-Chieh Chen, Sho-Jen Cheng, Cheng-Yu Chen
Summary: The study introduced a machine learning model for selecting and predicting EGFR and KRAS mutations in NSCLC patients using a minimal number of semantic radiomics features, with the genetic algorithm plus XGBoost classifier showing the best accuracy in detecting these mutations. This noninvasive machine learning-based model demonstrated robust prediction of EGFR and KRAS mutations in patients with NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Bin Zhang, Shaowei Dong, Jian Wang, Tuxiong Huang, Pan Zhao, Jing Xu, Dongcheng Liu, Li Fu, Lingwei Wang, Guangsuo Wang, Chang Zou
Summary: By using 3D printed patient derived xenograft models, this study identifies a NOTCH mutation as a predictor of response to EGFR-TKI therapy in LUAD. The NOTCH4(Delta L12_16) mutation increases the occurrence in EGFR-TKI-sensitive patients and sensitizes EGFR-TKI-resistant LUAD cells to the drug. This is mediated by reduced localization of NOTCH4 and down-regulation of HES1 expression. Inhibition of the NOTCH4-HES1 pathway can reverse EGFR-TKI resistance.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Qiwen Li, Li Ma, Bo Qiu, Yuzhi Wen, Wenhua Liang, Wanming Hu, Naibin Chen, Tian Zhang, Shuangbing Xu, Lingjuan Chen, Minzhang Guo, Yi Zhao, Songran Liu, Jinyu Guo, Junye Wang, Siyu Wang, Xin Wang, Qingsong Pang, Hao Long, Hui Liu
Summary: This retrospective study evaluated the efficacy and toxicity of adjuvant TKIs compared with chemotherapy in patients with EGFR-mutant stage III-pN2 lung adenocarcinoma. The results suggest that adjuvant TKIs may be a beneficial choice over adjuvant chemotherapy or combination systemic treatments, with potential for improved outcomes.
Article
Biochemistry & Molecular Biology
Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
Summary: The third-generation EGFR-TKIs have shown significant clinical achievements in NSCLC treatment, but acquired drug resistance remains a major limitation. The development of fourth-generation EGFR-TKIs targeting the triple mutant EGFR with C797S mutation has gained much attention. This review outlines the current panorama of fourth-generation EGFR-TKIs, focusing on their design strategy, binding mode, and antitumor activity. The challenges and prospects of fourth-generation EGFR-TKIs are also discussed.
BIOORGANIC CHEMISTRY
(2022)
Editorial Material
Oncology
David J. Cantor, Charu Aggarwal
Summary: KRAS-mutated non-small cell lung cancer (NSCLC) is the most prevalent genetic subtype of NSCLC, but targeted therapies are currently limited. Combination treatments of MEK inhibitors with chemotherapy have been extensively studied but have not shown promising results. This article discusses these studies and novel approaches for targeting KRAS-mutated NSCLC.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Roberto Chalela, Jose Gregorio Gonzalez-Garcia, Karys Khilzi, Victor Curull, Albert Sanchez-Font, Raquel Longaron, Maria Teresa Rodrigo-Calvo, Clara Martin-Ontiyuelo, Joaquim Gea, Beatriz Bellosillo
Summary: Driver mutations in non-tumoral lung cells were detected in a proportion of subjects with ADC, indicating their potential role in carcinogenesis. The presence of these mutations in the absence of coexisting mutations in the primary tumor was confirmed through highly sensitive PCR methods.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Review
Medicine, General & Internal
Xiaoli Chen, Dongmei Li, Kun Miao, Tao Shou, Wenjing Zhang
Summary: This paper reports a case of small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma. The characteristics of this case and the treatment after transformation are summarized, emphasizing the necessity of repeat biopsy and dynamic monitoring of genetic mutations.
Article
Oncology
Yue Hao, Manyi Xu, Jianan Jin, Jinfei Si, Chunwei Xu, Zhengbo Song
Summary: The efficacy and safety of second- and third-generation TKIs in NSCLC patients with uncommon EGFR mutations were compared, and no significant difference was found. They can be used for the treatment of patients with these mutations.
Article
Medicine, Research & Experimental
Linlin Yang, Zhefeng Li, Daniel W. Binzel, Peixuan Guo, Terence M. Williams
Summary: This study suggests that nanoparticles targeting mutant KRAS can effectively suppress cancer cell proliferation and migration, and enhance sensitivity to chemoradiotherapy in lung cancer. These findings highlight the potential of this nanoparticle-based platform as a novel treatment strategy for KRAS-driven human cancers.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2023)